Illumisite
Payments companies reported to CMS as associated with Illumisite. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Illumisite, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Illumisite
These are the largest totals companies reported as associated with Illumisite. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sandeep Khandhar | Fairfax, VA | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $63,072.59 |
| Erik Folch | Boston, MA | Pulmonary Disease | $56,308.87 |
| Bryan Benn | Cleveland, OH | Pulmonary Disease | $42,213.39 |
| Catherine Oberg | Torrance, CA | Pulmonary Disease | $41,448.56 |
| Amit Mahajan | Falls Church, VA | Internal Medicine | $33,361.35 |
| Jon Freels | Columbia, TN | Pulmonary Disease | $31,248.99 |
| Jonathan Kurman | Milwaukee, WI | Pulmonary Disease | $26,682.97 |
| Todd Hoopman | Coeur D Alene, ID | Pulmonary Disease | $24,546.17 |
| Otis Rickman | Nashville, TN | Pulmonary Disease | $22,715.43 |
| Hiren Mehta | Raleigh, NC | Pulmonary Disease | $22,521.72 |
Prescribed Illumisite?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.